Literature DB >> 23178154

α7 nicotinic acetylcholine receptors and their role in cognition.

Balázs Lendvai1, Ferenc Kassai, Agota Szájli, Zsolt Némethy.   

Abstract

The precise role of nicotinic acetylcholine receptors (nAChRs) in central cognitive processes still remains incompletely understood almost 150 years after its initial discovery. Central nAChRs are activated by acetylcholine, which functions in the extracellular space as a nonsynaptic messenger. Recently, a novel concept in the nAChR mode of operation has been described as a fast-type nonsynaptic transmission. In this review, we attempt to summarise the experimental findings that support the role of one of the most distributed receptor subtypes, the α7 nAChRs, and particularly focus on its procognitive effects following receptor activation. The basic characteristics of α7 nAChRs are discussed, from receptor homology to cellular-level functions. Synaptic plasticity is often implicated with α7 nAChRs on the basis of several diverse studies. Here, we provide a summary of the plastic features of the α7 receptor subtype and its role in higher level cognitive function. Finally, recent clinical evidence is reviewed, which demonstrates with increasing confidence the promise α7 nAChRs as a molecular target in future pharmacotherapy to prevent cognitive decline in various types of dementia, specifically, via the development of positive allosteric modulator compounds.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23178154     DOI: 10.1016/j.brainresbull.2012.11.003

Source DB:  PubMed          Journal:  Brain Res Bull        ISSN: 0361-9230            Impact factor:   4.077


  29 in total

1.  Boosting Endogenous Resistance of Brain to Ischemia.

Authors:  Fen Sun; Stephen R Johnson; Kunlin Jin; Victor V Uteshev
Journal:  Mol Neurobiol       Date:  2016-02-24       Impact factor: 5.590

2.  High therapeutic potential of positive allosteric modulation of α7 nAChRs in a rat model of traumatic brain injury: proof-of-concept.

Authors:  Joshua W Gatson; James W Simpkins; Victor V Uteshev
Journal:  Brain Res Bull       Date:  2015-01-31       Impact factor: 4.077

3.  Discovery of BNC375, a Potent, Selective, and Orally Available Type I Positive Allosteric Modulator of α7 nAChRs.

Authors:  Andrew J Harvey; Thomas D Avery; Laurent Schaeffer; Christophe Joseph; Belinda C Huff; Rajinder Singh; Christophe Morice; Bruno Giethlen; Anton A Grishin; Carolyn J Coles; Peter Kolesik; Stéphanie Wagner; Emile Andriambeloson; Bertrand Huyard; Etienne Poiraud; Dharam Paul; Susan M O'Connor
Journal:  ACS Med Chem Lett       Date:  2019-03-25       Impact factor: 4.345

Review 4.  Development of (18)F-labeled radiotracers for neuroreceptor imaging with positron emission tomography.

Authors:  Peter Brust; Jörg van den Hoff; Jörg Steinbach
Journal:  Neurosci Bull       Date:  2014-08-29       Impact factor: 5.203

Review 5.  Molecular function of α7 nicotinic receptors as drug targets.

Authors:  Cecilia Bouzat; Matías Lasala; Beatriz Elizabeth Nielsen; Jeremías Corradi; María Del Carmen Esandi
Journal:  J Physiol       Date:  2017-11-29       Impact factor: 5.182

6.  Role of neuronal nicotinic acetylcholine receptors (nAChRs) on learning and memory in zebrafish.

Authors:  Daniela Braida; Luisa Ponzoni; Roberta Martucci; Fabio Sparatore; Cecilia Gotti; Mariaelvina Sala
Journal:  Psychopharmacology (Berl)       Date:  2013-12-06       Impact factor: 4.530

7.  A human-specific, truncated α7 nicotinic receptor subunit assembles with full-length α7 and forms functional receptors with different stoichiometries.

Authors:  Matías Lasala; Jeremías Corradi; Ariana Bruzzone; María Del Carmen Esandi; Cecilia Bouzat
Journal:  J Biol Chem       Date:  2018-05-21       Impact factor: 5.157

8.  Phase IIb Trial of an α7 Nicotinic Receptor Partial Agonist With and Without Nicotine Patch for Withdrawal-Associated Cognitive Deficits and Tobacco Abstinence.

Authors:  Randi Melissa Schuster; Gladys N Pachas; Luke Stoeckel; Corinne Cather; Mireya Nadal; David Mischoulon; David A Schoenfeld; Haiyue Zhang; Christine Ulysse; Elisabeth B Dodds; Sara Sobolewski; Vicenta Hudziak; Ailish Hanly; Maurizio Fava; A Eden Evins
Journal:  J Clin Psychopharmacol       Date:  2018-08       Impact factor: 3.153

9.  ABT-089, but not ABT-107, ameliorates nicotine withdrawal-induced cognitive deficits in C57BL6/J mice.

Authors:  Emre Yildirim; David A Connor; Thomas J Gould
Journal:  Behav Pharmacol       Date:  2015-04       Impact factor: 2.293

10.  The α7 nicotinic receptor agonist ABT-107 decreases L-Dopa-induced dyskinesias in parkinsonian monkeys.

Authors:  Danhui Zhang; Matthew McGregor; Michael W Decker; Maryka Quik
Journal:  J Pharmacol Exp Ther       Date:  2014-07-17       Impact factor: 4.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.